In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

After winning an initial U.S. nod in July 2023, Beyfortus has gone on to do gangbusters for Sanofi and AZ, growing total sales 9.5% last year for a total haul of 1.78 billion euros (roughly $2.1 ...

In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

The new audio show builds on recent efforts by AbbVie to boost awareness of its teams’ patient-driven work, including in the “I Am” corporate campaign that launched last summer and spotlights both ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs.  < | As ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

In the seven-plus years since Bayer closed its mammoth buyout of Monsanto, the combined company has struggled to contain ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...